(Reuters) – Inovio Pharmaceuticals Inc is focused on launching the global late-stage trial of its COVID-19 vaccine candidate next month, Chief Executive Officer Joseph Kim said during a post-earnings call on Monday.
In May, Inovio said it will begin a global late-stage study of its vaccine candidate, INO-4800, in summer this year, after it was safe, well-tolerated and produced immune response against the new coronavirus in a mid-stage clinical trial.
The company started developing INO-4800 last year, but fell behind rivals after the U.S. Food and Drug Administration put a part of the study on hold for more information on the vaccine delivery device.
(Reporting by Mrinalika Roy in Bengaluru and Carl O’Donnell in New York; Editing by Devika Syamnath)
